Reply to Verheyden and Demanet
Leukemia ( Dr Verheyden and Dr Demanet 1 raised several interesting questions in their comment to our letter. 2 Following their suggestion, we additionally analyzed chronic myelogenous leukemia (CML) patients and their donors with regard to homozygosity for haplotype A and killer immunoglobuline-like receptor (KIR)1D to identify subjects lacking any functional activating KIR. In the respective groups, the frequencies were 25.8 and 16.1%. As this difference was not statistically significant, it may be hypothesized that the effect of activating KIRs is rather qualitative and restricted to KIR2DS4 while other activating KIRs do not appear to play a role. Indeed, the frequencies of KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1 were similar among CML patients and their donors. As well, the median sum of all activating KIRs was comparable (data not shown).
In our study, we used human leukocyte antigen (HLA)-matched bone marrow donors as a representative control group, considering that (i) HLA genotype is associated with the occurrence and the age-at-onset of CML 3, 4 and (ii) KIR-HLA ligand interactions appear to play a role in the pathogenesis of leukemia.
5 HLA-identical siblings constituted 32.3% of donors in a cohort of CML, 36.8% in acute myeloid leukemia and 33.3% in acute lymphoblastic leukemia (P ¼ NS). However, as suggested by Verheyden and Demanet, 1 we additionally looked at data available for the Polish population (I Nowak, E Majorczyk, P Kusnierczyk, unpublished data). Among 363 healthy individuals, 63.2% were KIR2DS4n001 À /KIR1D þ compared to 77.4% in our CML cohort (P ¼ 0.08).
We feel that our results on activating KIR2DS4 are complementary to those previously published by Verheyden et al., stressing the role of inhibitory KIRs. 5, 6 In both cases, there is rationale to verify the findings in large populations of patients with particular subtypes of leukemia. 
